Diabetic Nephropathy

IL-6 Levels Linked With Progression of Diabetic Kidney Disease

Publish Date June 11, 2021

In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.

Renoprotective Effect of SGLT2 Inhibitors Mediated Largely by Hematocrit

Publish Date June 10, 2021

Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.

Semaglutide Effective in High-Risk Diabetic Kidney Disease

Publish Date June 10, 2021

More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.

Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy

Publish Date June 10, 2021

Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.

Finerenone Improves Cardiovascular Outcomes in Patients With Diabetic Kidney Disease

Publish Date May 13, 2021

The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.

Afro-Caribbean Ethnicity Linked to Non-Linear eGFR Decline in DKD

Publish Date May 11, 2021

Non-linear renal function decline frequently occurs in patients with type 2 diabetes and is associated with faster progression to end-stage kidney disease.

Hypertension, Albuminuria Common in Pediatric Type 2 Diabetes

Publish Date May 6, 2021

The prevalence of hypertension and albuminuria in pediatric patients with type 2 diabetes varies by race.

Dapagliflozin Reduces Risk for Kidney Events in IgA Nephropathy

Publish Date May 5, 2021

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

Decreased UACR Linked to Reduced Risk for Cardiovascular, Renal Events in T2D

Publish Date March 5, 2021

Urinary albumin-to-creatinine ratio values are often used to guide treatment decisions as albuminuria is known to be a strong predictor of cardiovascular and renal events.

Albuminuria Reduction Greater With SGLT2 Inhibitor, ERA Combo

Publish Date March 17, 2021

A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.